April - June 2011
June 3, 2011
Eli Lilly and Company
Takeda Pharmaceutical Company Limited
Seoul, Korea, and Osaka, Japan, June 3, 2011 – Eli Lilly and Company (Lilly) (NYSE:LLY) and Takeda Pharmaceutical Company Limited (Takeda) (TSE:4502) announced today that they have entered into an exclusive partnership to market Evista (raloxifene HCl tablets) in 7 Asian markets (Korea, Hong Kong, Macau, Malaysia, Philippines, Singapore and Thailand, “Territory”) as of May 20, 2011. In addition, Takeda’s promotion of Evista has commenced in the Territory.
Evista is approved and marketed for the treatment and prevention of Osteoprorosis in postmenopausal women in the Territory and for breast cancer risk reduction in Philippines, Singapore and Thailand.
Under the terms of the agreement, the marketing and distribution rights of Evista will be transferred to Takeda in the Territory. In addition, Takeda will assume ownership of the trademark, marketing authorization and related regulatory matters for Evista in the Territory and in return Lilly will receive cash payment from Takeda. Lilly also retains patent ownership. Transition activities between Lilly and Takeda began late May. Takeda will assume responsibility for Evista once transition activities in each market are complete.
“This agreement is good for our customers, including patients and physicians, because Takeda intends to commit additional resources to support Evista in affected markets in Asia,” said Eberhard Ludewigs, vice president, AMERASIA Operations of Lilly. “The agreement also provides Lilly guaranteed income and gives us the opportunity to invest further in diabetes, oncology and neuroscience. Our commitment to patients suffering from osteoporosis, and to their physicians, remains firm. Evista outside of the Territory will not be affected by this agreement.”
“We are enhancing business in Asia, which is one of our main focus, by various initiatives including strengthening of sales structure. This partnership with Lilly offers the potential for Takeda to accelarate our business in this region.” said Haruhiko Hirate, Corporate Officer, Senior Vice President, International Operations (Asia) of Takeda. “We will work closely with Lilly to implement a smooth transition and ensure patients and physicians have the products and information they need.”
EVISTA (raloxifene HCl) is a prescription medication that prevents and treats osteoporosis in women past menopause. EVISTA is neither an estrogen nor a hormone. EVISTA is a selective estrogen receptor modulator, or SERM (recently classified by the FDA as an estrogen agonist/antagonist). EVISTA prevents and treats osteoporosis by actually helping make bones stronger and less likely to break.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
|Corporate Contacts: Lilly||Corporate Contacts: Takeda|
|Sunyoung Lee||Mihoko Shinomiya|
|Communications Manager Lilly Korea||Takeda Pharmaceutical Company Limited|
|Mob: +82- 10- 7566- 5846
|81- 3- 3278- 2037|